ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2024
Diagnostic Value of Plasma Long Non-coding SLC26A4 Antisense RNA 1 Combined with Magnetic Resonance Imaging in Rectal Cancer.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: The prevalence of rectal cancer is increasing every year due to changes in living and eating habits. Early diagnosis contributes to the treatment and survival of patients. This study investigated the feasibility of employing SLC26A4-AS1 combined with magnetic resonance imaging (MRI) for diagnosing rectal cancer. Materials and Methods: The current study involved 125 patients with rectal cancer and an equal number of healthy individuals. The study focused on assessing the relationship between SLC26A4-AS1 expression and clinical data among patients with rectal cancer by analyzing the expression levels. MRI blood perfusion parameters (Ktrans, Kep, Ve, and incremental area under the curve (iAUC)) were measured in the patients with rectal cancer. The regulation of SLC26A4-AS1 on the biological function of rectal cancer cells was analyzed by Cell Counting Kit-8 (CCK-8) method, flow cytometry, and Transwell assay. Furthermore, luciferase activity assays and RNA-binding protein immunoprecipitation assay (RIP) were conducted to elucidate the relationship between SLC26A4-AS1 and microRNA-3174 (miR-3174). Results: A significant reduction in SLC26A4-AS1 expression was observed in rectal cancer alongside a significant increase in miR-3174 levels. SLC26A4-AS1 expression was negatively correlated with Ktrans and Kep values, but not with Ve or iAUC values. Cell experiments confirmed the inhibitory effect of SLC26A4-AS1 overexpression on the growth of rectal cancer cells. Additionally, SLC26A4-AS1 sponged miR-3174 mediated the progression of rectal cancer. The enriched miR-3174 may counteract the suppression of the biological activity of oe-SLC26A4-AS1 on rectal cancer cells. Conclusion: SLC26A4-AS1 may serve as a diagnostic tool for rectal cancer, mediating tumor progression by directly targeting miR-3174.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.